EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Diagnostic and Clinical Impact of Imaging Modality on PSA Density: TRUS Versus MRI in Gray-Zone Prostate Cancer

Davut Unsal Capkan, Mehmet Solakhan iD

Current Oncology · 16.04.2026 · 33 (4) · 221

DOI: 10.3390/curroncol33040221 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Current Oncology, online erschienen am 16.04.2026. Verfasst von Davut Unsal Capkan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Medical Point Hospital, 27060 Gaziantep, Turkey. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostate-Specific Antigen, Magnetic Resonance Imaging. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In this study, it was aimed to compare transrectal ultrasound (TRUS)- and magnetic resonance imaging (MRI)-derived prostate-specific antigen density (PSAD) in patients with gray-zone PSA levels (4–10 ng/mL), evaluate their diagnostic performance for clinically significant prostate cancer (csPCa), and assess the clinical implications of reclassification across commonly used thresholds.

Methods

We retrospectively analyzed 202 men who underwent both TRUS and multiparametric MRI between January 2020 and June 2025. Prostate volume was measured using the ellipsoid formula for TRUS and contour-based planimetry for MRI. PSA density (PSAD) was calculated as total PSA (tPSA, ng/mL) divided by prostate volume (mL) for each modality: TRUS-PSAD and MRI-PSAD. Agreement between modalities was evaluated using Bland–Altman plots and correlation analyses. Reclassification at PSAD thresholds of 0.15, 0.20, and 0.30 ng/mL/mL was assessed using Cohen’s κ and net reclassification improvement (NRI). Diagnostic performance for csPCa (ISUP grade group ≥ 2) was evaluated with ROC analysis and the DeLong test. Inter- and intra-observer reproducibility was determined using intraclass correlation coefficients (ICC) and Cohen’s κ. Clinical utility was assessed by decision curve analysis (DCA).

Results

MRI-derived prostate volumes were significantly lower than TRUS-derived volumes (median 47.0 vs. 52.5 mL, p < 0.001), resulting in higher MRI-PSAD values (median 0.14 vs. 0.12 ng/mL/mL, p < 0.001). Bland–Altman analysis demonstrated a negative bias for prostate volume (−3.2 mL) and a positive bias for PSAD (+0.03). Strong correlations were observed between TRUS and MRI measurements (r = 0.96 for volume and r = 0.94 for PSAD). MRI-PSAD frequently reclassified patients into higher risk categories, yielding positive net reclassification improvement for cancer cases across all thresholds, while introducing some negative reclassification among non-cancer cases. ROC analysis showed comparable overall diagnostic performance between TRUS-PSAD and MRI-PSAD (AUC 0.681 vs. 0.679, p = 0.91). However, MRI-PSAD demonstrated higher sensitivity at predefined thresholds at the expense of reduced specificity, reflecting a threshold-dependent shift rather than improved discrimination. Reproducibility was higher for MRI-derived measurements (ICC = 0.94; κ = 0.83) compared with TRUS (ICC = 0.86; κ = 0.71). Decision curve analysis indicated that MRI-PSAD, particularly when combined with PI-RADS ≥ 3, provided the greatest net clinical benefit at lower threshold probabilities (5–15%).

Conclusions

MRI-derived PSA density produces systematically higher values than TRUS-based measurements due to inherent differences in prostate volume estimation. While this results in increased sensitivity at standard thresholds, overall discrimination remains unchanged. These findings support the use of modality-specific PSAD thresholds rather than uniform cutoffs across imaging techniques. In clinical practice, MRI-PSAD may provide additional value when interpreted in conjunction with PI-RADS, primarily through improved threshold calibration rather than enhanced diagnostic accuracy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstate-Specific AntigenMagnetic Resonance ImagingHumansMaleRetrospective StudiesAgedUltrasonographyMiddle AgedClinical Relevance

Stichwörter der Autor:innen

MRIPI-RADSPSA densityTRUSdecision curve analysisdiagnostic performanceprostate cancer

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Radiology, Medical Point Hospital, 27060 Gaziantep, Turkey.
  • Department of Urology, Medical Point Hospital, 27060 Gaziantep, Turkey.

ORCID-Profile: Mehmet Solakhan

Zitieren

APA

Capkan, D. U., & Solakhan, M. (2026). Diagnostic and Clinical Impact of Imaging Modality on PSA Density: TRUS Versus MRI in Gray-Zone Prostate Cancer. Current Oncology, 33(4), 221. https://doi.org/10.3390/curroncol33040221

Vancouver

Capkan DU, Solakhan M. Diagnostic and Clinical Impact of Imaging Modality on PSA Density: TRUS Versus MRI in Gray-Zone Prostate Cancer. Current Oncology. 2026;33(4):221. doi:10.3390/curroncol33040221

BibTeX
@article{Capkan2026,
  author = {Capkan, Davut Unsal and Solakhan, Mehmet},
  title = {Diagnostic and Clinical Impact of Imaging Modality on PSA Density: TRUS Versus MRI in Gray-Zone Prostate Cancer},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {4},
  pages = {221},
  doi = {10.3390/curroncol33040221}
}
Kostenlos starten →